Last reviewed 2026-05-20 · How we verify

Metilmercadon (NIFURATEL)

Phase 2 active Small molecule ✓ Verified May 2026

Metilmercadon (generic name: NIFURATEL) is a nifuratel drug. It is currently in Phase 2 development.

Nifuratel works by inhibiting the growth of microorganisms.

Metilmercadon is a small molecule with synonyms including INIMUR, MACMIROR, MAGMILOR, METHYLMERCADONE, NF-113, and NIFURATEL.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NIFURATEL
Drug class	nifuratel
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body is a city, and microorganisms are like unwanted visitors. Nifuratel helps keep them from multiplying and taking over by blocking their ability to grow and divide. This helps your body's natural defenses to keep you healthy.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Metilmercadon CI brief — competitive landscape report
Metilmercadon updates RSS · CI watch RSS

Frequently asked questions about Metilmercadon

What is Metilmercadon?

Metilmercadon (NIFURATEL) is a nifuratel drug.

How does Metilmercadon work?

Nifuratel works by inhibiting the growth of microorganisms.

What is the generic name of Metilmercadon?

NIFURATEL is the generic (nonproprietary) name of Metilmercadon.

What drug class is Metilmercadon in?

Metilmercadon belongs to the nifuratel class. See all nifuratel drugs at /class/nifuratel.

What development phase is Metilmercadon in?

Metilmercadon is in Phase 2.

Drug class: All nifuratel drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing